NCT05389423 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05389423
Title	Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	National Cancer Institute (NCI)
Indications	non-Hodgkin lymphoma
Therapies	Cyclophosphamide + Doxorubicin + Etoposide + Pomalidomide + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Pomalidomide + Prednisone + Rituximab + Vincristine Sulfate
Age Groups:	adult \| senior
Covered Countries	USA

NCT05389423
Clinical Trial Detail